SCHEMBL6285838

SCHEMBL6285838

COc1ccc(-c2cc3cnncc3[nH]2)cc1C(N)c1cccnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.41
RIPK1 Q13546 2/20 0.39
CYP19A1 P11511 3/20 0.38
AAK1 Q2M2I8 2/20 0.37
TLR8 Q9NR97 2/20 0.36
TLR7 Q9NYK1 2/20 0.36
PDE4A P27815 2/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
NPC1 O15118 3/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
RAB9A P51151 2/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286923 0.92 NPY5R (0.41) NPY5RRIPK1CYP19A1AAK1TLR8
SCHEMBL6287054 0.92 CLK2 (0.41) NPY5RRIPK1CYP19A1AAK1TLR8
SCHEMBL6287306 0.85 RIPK1 (0.56) NPY5RRIPK1CCNB2CDK1CCNB1
SCHEMBL6279240 0.85 RIPK1 (0.43) NPY5RRIPK1CYP19A1AAK1CCNB2
SCHEMBL6282858 0.85 NPY5R (0.41) NPY5RRIPK1AAK1TLR8TLR7
SCHEMBL6282546 0.84 NPY5R (0.43) NPY5RRIPK1CYP19A1AAK1TLR8
SCHEMBL6285938 0.84 RIPK1 (0.47) NPY5RRIPK1CCNB2CDK1CCNB1
SCHEMBL6287083 0.83 NPY5R (0.41) NPY5RRIPK1AAK1TLR8TLR7
SCHEMBL6286058 0.81 CCNB2 (0.49) NPY5RRIPK1CCNB2CDK1CCNB1
SCHEMBL6286952 0.79 NPY5R (0.39) NPY5RRIPK1CYP19A1AAK1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B NPY5R 273/4885RIPK1 2043/4885CYP19A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.